Ironwood Pharmaceuticals, which is developing a new treatment for irritable bowel syndrome and constipation, will see its quiet period end on Sunday, Mar. 14. On Feb. 2, the company raised $188 million by offering 16.7 million shares at $11.25, below the range of $14-$16. J.P. Morgan, Morgan Stanley and Credit Suisse acted as lead managers on the deal.
